A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

• Status: Recruiting
• Trial end date: 2023-01-18
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Ipilimumab; Linrodostat; Nivolumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Advanced Renal Cell Carcinoma

• Must have at least 1 lesion with measurable disease

• Life expectancy of at least 3 months

• Karnofsky Performance Status (KPS) must be =>70%

Exclusion Criteria:

• Patients/subjects with suspected or known central nervous system metastases unless adequately treated

• Patients/subjects with autoimmune disease

• Patients/subjects who need daily oxygen therapy

Other protocol defined inclusion/exclusion criteria could apply